Back to Search
Start Over
Future perspectives in the pharmacological treatment of atrial fibrillation and ventricular arrhythmias in heart failure.
- Source :
-
Current pharmaceutical design [Curr Pharm Des] 2015; Vol. 21 (8), pp. 1011-29. - Publication Year :
- 2015
-
Abstract
- Heart failure (HF) is a clinical syndrome characterized by significant impairment of cardiac ventricular function. Atrial fibrillation (AF) is the most commonly observed sustained arrhythmia in clinical practice. Both HF and AF are associated with increased morbidity and mortality and their prevalence increases with age. Approximately 50% of patients with moderate HF die due to ventricular fibrillation that leads to sudden cardiac death. Patients with AF exhibit increased mortality due to HF and stroke. HF and AF often co-exist, and the development of the other condition further deteriorates prognosis. Both chronic HF and AF lead to structural and electrophysiological changes in the heart called remodeling, modifying therapeutic targets including those for antiarrhythmic intervention. Current pharmacological treatment of arrhythmias has major limitations due to low efficacy and serious adverse effects. In this review, the main aspects of electrical remodeling in HF and AF are discussed along with possible novel targets identified for future pharmacological antiarrhythmic therapy.
- Subjects :
- Anti-Arrhythmia Agents pharmacology
Arrhythmias, Cardiac etiology
Atrial Fibrillation etiology
Humans
Ventricular Function drug effects
Ventricular Remodeling drug effects
Ventricular Remodeling physiology
Anti-Arrhythmia Agents therapeutic use
Arrhythmias, Cardiac drug therapy
Atrial Fibrillation drug therapy
Heart Failure complications
Subjects
Details
- Language :
- English
- ISSN :
- 1873-4286
- Volume :
- 21
- Issue :
- 8
- Database :
- MEDLINE
- Journal :
- Current pharmaceutical design
- Publication Type :
- Academic Journal
- Accession number :
- 25354185
- Full Text :
- https://doi.org/10.2174/1381612820666141029101305